Lidbree (Lidocaine)

Lidocaine works by blocking voltage‑gated sodium channels on nerve membranes, which prevents the rapid influx of sodium ions needed for depolarisation. This stabilises the neuronal membrane and stops the initiation and propagation of pain signals, producing a reversible loss of sensation in the area where it is applied.

The appropriate dose of Lidbree is determined by the prescribing clinician based on the specific procedure, patient characteristics, and clinical setting. Dosage may vary for intracervical versus intrauterine administration, and the prescriber will calculate the volume needed to achieve effective local anaesthesia while minimising systemic exposure.

Safety data for Lidbree in pregnancy and lactation are limited. The decision to use lidocaine‑containing products in pregnant or breastfeeding patients should be made by the treating physician after weighing potential benefits against possible risks to the mother and fetus or infant.

To order Lidbree, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and assistance with import documentation.

Lidbree (lidocaine) offers a rapid onset of action and moderate duration, making it suitable for short‑procedural anaesthesia. Compared with longer‑acting agents such as bupivacaine, lidocaine provides quicker recovery of sensation but may require repeat dosing for extended procedures. Its safety profile is well‑established, though systemic toxicity must still be monitored.

Lidbree should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Ensure the container is tightly sealed and avoid exposure to extreme temperatures, which could affect the stability of the lidocaine solution.

Lidbree is administered by a trained healthcare professional via intracervical or intrauterine injection. The solution is injected directly into the cervical tissue or uterine cavity using a sterile syringe and appropriate needle, following aseptic technique and confirming correct placement before delivery.

Serious risks include allergic reactions such as angio‑edema or anaphylaxis, seizures, cardiac arrhythmias (e.g., ventricular tachycardia), methemoglobinemia, and respiratory depression. Immediate medical attention is required if any of these symptoms develop after administration.

Lidbree should be avoided in individuals with a known hypersensitivity to lidocaine or other amide‑type local anesthetics, patients with severe hepatic impairment, and those with pre‑existing cardiac conduction abnormalities unless the benefits clearly outweigh the risks. Contra‑indications should be confirmed by the prescribing clinician.